Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma

Journal of Virology

Volumn 83, Issue 15, 2009, Pages 7507-7516

  Verheije, Monique H ^a   Lamfers, Martine L M ^b   Würdinger, Thomas ^a,c,d   Grinwis, Guy C M ^a   Gerritsen, Winald R ^c   Van Beusechem, Victor W ^c   Rottier, Peter J M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTIDINE; ONCOLYTIC MURINE HEPATITIS CORONAVIRUS; ONCOLYTIC VIRUS; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG; VIRUS RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL KILLING; CHO CELL; CONTROLLED STUDY; CORONAVIRUS; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MURINE HEPATITIS CORONAVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; RNA RECOMBINATION; TREATMENT OUTCOME; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS RECOMBINANT; VIRUS REPLICATION; XENOGRAFT;

ANIMALS; BRAIN; CELL LINE, TUMOR; FEMALE; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MURINE HEPATITIS VIRUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

ANIMALIA; CORONAVIRUS; MURINAE; MURINE HEPATITIS VIRUS; MUS; RNA VIRUSES;

EID: 67650885885     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00495-09     Document Type: Article

References (50)

1. Allen, C., G. Paraskevakou, C. Liu, I. D. Iankov, P. Zollman, and E. Galanis. 2008. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin. Biol. Ther. 8:213-220.
2. Cattaneo, R., T. Miest, E. V. Shashkova, and M. A. Barry. 2008. Reprogrammed viruses as cancer therapeutics: targeted, armed, and shielded. Nat. Rev. Microbiol. 6:529-540.
3. Cervantes-Garcia, D., R. Ortiz-Lopez, N. Mayek-Perez, and A. Rojas-Martinez. 2008. Oncolytic virotherapy. Ann. Hepatol. 7:34-45.
4. Coffey, M. C., J. E. Strong, P. A. Forsyth, and P. W. Lee. 1998. Reovirus therapy of tumors with activated Ras pathway. Science 282:1332-1334.
5. Csatary, L. K., G. Gosztonyi, J. Szeberenyi, Z. Fabian, V. Liszka, B. Bodey, and C. M. Csatary. 2004. MTH-68/H oncolytic viral treatment in human high-grade gliomas. J. Neurooncol. 67:83-93.
6. de Haan, C. A., M. de Wit, L. Kuo, C. Montalto-Morrison, B. L. Haagmans, S. R. Weiss, P. S. Masters, and P. J. Rottier. 2003. The glycosylation status of the murine hepatitis coronavirus M protein affects the interferogenic capacity of the virus in vitro and its ability to replicate in the liver but not the brain. Virology 312:395-406.
7. de Haan, C. A., P. S. Masters, X. Shen, S. Weiss, and P. J. Rottier. 2002. The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host. Virology 296:177-189.
8. de Haan, C. A., L. van Genne, J. N. Stoop, H. Volders, and P. J. Rottier. 2003. Coronaviruses as vectors: position dependence of foreign gene expression. J. Virol. 77:11312-11323.
9. Ekstrand, A. J., C. D. James, W. K. Cavenee, B. Seliger, R. F. Pettersson, and V. P. Collins. 1991. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 51:2164-2172.
10. Elroy-Stein, O., and B. Moss. 1990. Cytoplasmic expression system based on constitutive synthesis of bacteriophage T7 RNA polymerase in mammalian cells. Proc. Natl. Acad. Sci. USA 87:6743-6747.
11. Frederick, L., X. Y. Wang, G. Eley, and C. D. James. 2000. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 60:1383-1387.
12. Freeman, A. I., Z. Zakay-Rones, J. M. Gomori, E. Linetsky, L. Rasooly, E. Greenbaum, S. Rozenman-Yair, A. Panet, E. Libson, C. S. Irving, E. Galun, and T. Siegal. 2006. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 13:221-228.
13. Fuerst, T. R., E. G. Niles, F. W. Studier, and B. Moss. 1986. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. USA 83:8122-8126.
14. Galanis, E., R. Vile, and S. J. Russell. 2001. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit. Rev. Oncol. Hematol. 38:177-192.
15. Gallagher, T. M. 1997. A role for naturally occurring variation of the murine coronavirus spike protein in stabilizing association with the cellular receptor. J. Virol. 71:3129-3137.
16. Guo, Z. S., S. H. Thorne, and D. L. Bartlett. 2008. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim. Biophys. Acta 1785:217-231.
17. Jiang, H., F. McCormick, F. F. Lang, C. Gomez-Manzano, and J. Fueyo. 2006. Oncolytic adenoviruses as antiglioma agents. Expert Rev. Anticancer Ther. 6:697-708.
18. Kaufmann, M., P. Lindner, A. Honegger, K. Blank, M. Tschopp, G. Capitani, A. Pluckthun, and M. G. Grutter. 2002. Crystal structure of the anti-His tag antibody 3D5 single-chain fragment complexed to its antigen. J. Mol. Biol. 318:135-147.
19. Kuo, L., G. J. Godeke, M. J. Raamsman, P. S. Masters, and P. J. Rottier. 2000. Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier. J. Virol. 74:1393-1406.
20. Lamfers, M. L., D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen. 2005. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res. 65:9398-9405.
21. Libermann, T. A., H. R. Nusbaum, N. Razon, R. Kris, I. Lax, H. Soreq, N. Whittle, M. D. Waterfield, A. Ullrich, and J. Schlessinger. 1985. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313:144-147.
22. Liu, T. C., and D. Kirn. 2008. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther. 15:877-884.
23. Lowe, P. N., and R. H. Skinner. 1994. Regulation of Ras signal transduction in normal and transformed cells. Cell Signal 6:109-123.
24. Lun, X., D. L. Senger, T. Alain, A. Oprea, K. Parato, D. Stojdl, B. Lichty, A. Power, R. N. Johnston, M. Hamilton, I. Parney, J. C. Bell, and P. A. Forsyth. 2006. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J. Natl. Cancer Inst. 98:1546-1557.
25. Lun, X., W. Yang, T. Alain, Z. Q. Shi, H. Muzik, J. W. Barrett, G. McFadden, J. Bell, M. G. Hamilton, D. L. Senger, and P. A. Forsyth. 2005. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res. 65:9982-9990.
26. Marcato, P., M. Shmulevitz, D. Pan, D. Stoltz, and P. W. Lee. 2007. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol. Ther. 15:1522-1530.
27. Martuza, R. L., A. Malick, J. M. Markert, K. L. Ruffner, and D. M. Coen. 1991. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854-856.
28. Miller, C. R., D. J. Buchsbaum, P. N. Reynolds, J. T. Douglas, G. Y. Gillespie, M. S. Mayo, D. Raben, and D. T. Curiel. 1998. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 58:5738-5748.
29. Nakamura, T., K. W. Peng, M. Harvey, S. Greiner, I. A. Lorimer, C. D. James, and S. J. Russell. 2005. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. 23:209-214.
30. Nemunaitis, J., and J. Edelman. 2002. Selectively replicating viral vectors. Cancer Gene Ther. 9:987-1000.
31. Nishikawa, R., X. D. Ji, R. C. Harmon, C. S. Lazar, G. N. Gill, W. K. Cavenee, and H. J. Huang. 1994. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA 91:7727-7731.
32. Norman, K. L., K. Hirasawa, A. D. Yang, M. A. Shields, and P. W. Lee. 2004. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc. Natl. Acad. Sci. USA 101:11099-11104.
33. Ozduman, K., G. Wollmann, J. M. Piepmeier, and A. N. van den Pol. 2008. Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J. Neurosci. 28:1882-1893.
34. Pedersen, N. C., J. F. Boyle, K. Floyd, A. Fudge, and J. Barker. 1981. An enteric coronavirus infection of cats and its relationship to feline infectious peritonitis. Am. J. Vet. Res. 42:368-377.
35. Ring, C. J. 2002. Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol. 83:491-502.
36. Rottier, P. J., M. C. Horzinek, and B. A. van der Zeijst. 1981. Viral protein synthesis in mouse hepatitis virus strain A59-infected cells: effect of tunicamycin. J. Virol. 40:350-357.
37. Russell, S. J., and K. W. Peng. 2007. Viruses as anticancer drugs. Trends Pharmacol. Sci. 28:326-333.
38. Sarma, J. D., E. Scheen, S. H. Seo, M. Koval, and S. R. Weiss. 2002. Enhanced green fluorescent protein expression may be used to monitor murine coronavirus spread in vitro and in the mouse central nervous system. J. Neurovirol. 8:381-391.
39. Sonabend, A. M., I. V. Ulasov, Y. Han, and M. S. Lesniak. 2006. Oncolytic adenoviral therapy for glioblastoma multiforme. Neurosurg. Focus 20:E19.
40. Steffens, S., J. Tebbets, C. M. Kramm, D. Lindemann, A. Flake, and M. Sena-Esteves. 2004. Transduction of human glial and neuronal tumor cells with different lentivirus vector pseudotypes. J. Neurooncol. 70:281-288.
41. Sugawa, N., A. J. Ekstrand, C. D. James, and V. P. Collins. 1990. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. USA 87:8602-8606.
42. Vennema, H., L. Heijnen, A. Zijderveld, M. C. Horzinek, and W. J. Spaan. 1990. Intracellular transport of recombinant coronavirus spike proteins: implications for virus assembly. J. Virol. 64:339-346.
43. Verheije, M. H., T. Wurdinger, V. W. van Beusechem, C. A. de Haan, W. R. Gerritsen, and P. J. Rottier. 2006. Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter. J. Virol. 80:1250-1260.
44. Waehler, R., S. J. Russell, and D. T. Curiel. 2007. Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet. 8:573-587.
45. Wickham, T. J. 2003. Ligand-directed targeting of genes to the site of disease. Nat. Med. 9:135-139.
46. Wong, A. J., J. M. Ruppert, S. H. Bigner, C. H. Grzeschik, P. A. Humphrey, D. S. Bigner, and B. Vogelstein. 1992. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. USA 89:2965-2969.
47. Wurdinger, T., M. H. Verheije, K. Broen, B. J. Bosch, B. J. Haijema, C. A. de Haan, V. W. van Beusechem, P. J. Rottier, and W. R. Gerritsen. 2005. Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor. J. Virol. 79:15314-15322.
48. Wurdinger, T., M. H. Verheije, M. Raaben, B. J. Bosch, C. A. de Haan, V. W. van Beusechem, P. J. Rottier, and W. R. Gerritsen. 2005. Targeting nonhuman coronaviruses to human cancer cells using a bispecific single-chain antibody. Gene Ther. 12:1394-1404.
49. Yamazaki, H., Y. Ohba, N. Tamaoki, and M. Shibuya. 1990. A deletion mutation within the ligand-binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Jpn. J. Cancer Res. 81:773-779.
50. Yount, B., M. R. Denison, S. R. Weiss, and R. S. Baric. 2002. Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J. Virol. 76:11065-11078.